Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting

Although rituximab is generally well‐tolerated, infusion‐related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low‐speed infusion rates have been recommended. Consequently, intravenous (i.v....

Descripción completa

Detalles Bibliográficos
Autores principales: Muntañola, Ana, Arguiñano‐Pérez, José María, Dávila, Julio, de Villambrosia, Sonia González, Carpio, Cecilia, Jiménez‐Ubieto, Ana, Salar, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926065/
https://www.ncbi.nlm.nih.gov/pubmed/36385738
http://dx.doi.org/10.1111/cts.13450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926065/
https://www.ncbi.nlm.nih.gov/pubmed/36385738
http://dx.doi.org/10.1111/cts.13450

Ejemplares similares